Accuray Launches Stellar Solution to Transform Personalized Adaptive Radiotherapy for Cancer Patients

Accuray Unveils the Stellar Solution to Revolutionize Adaptive Radiotherapy

Accuray Incorporated announces the launch of its groundbreaking Accuray Stellar™ Solution, aiming to transform adaptive radiotherapy for cancer patients. The innovative system, which will be showcased at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco, is designed as a comprehensive suite of tools that empowers clinical teams to deliver highly personalized radiotherapy tailored to individual patient needs. The Accuray Stellar is configured from the Radixact® Treatment Delivery System and seeks to simplify the incorporation of adaptive radiotherapy techniques into everyday clinical practice, regardless of the patient's stage in their cancer journey.

The Accuray Stellar Solution is built to enhance the precision of cancer treatments, with the potential to improve tumor control and increase survival rates, as noted by Suzanne Winter, the company's president and CEO. It supports a variety of radiation delivery methods, including image-guided radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and surface-guided radiation therapy (SGRT). This versatility allows it to address common cancer types such as breast, prostate, lung, and head and neck cancers, while also catering to complex cases like total marrow irradiation. By leveraging real-time motion tracking and correction capabilities, the system adapts to changes in tumor size or shape during treatment, ensuring optimal delivery of care.

Accuray's commitment to personalized cancer care is further reflected in the Stellar Solution's ability to integrate seamlessly with both proprietary software and hardware, as well as third-party technologies. This integration enhances the treatment workflow, allowing for streamlined operations and improved patient outcomes. The Stellar Solution exemplifies Accuray's dedication to innovating with purpose and compassion, promising to broaden access to transformative cancer therapies and solidifying the company's position as a leader in the adaptive radiotherapy space.

In addition to the Stellar Solution, Accuray continues to explore advancements in cancer treatment technologies. The company focuses on developing solutions that not only meet the current demands of clinical practice but also anticipate future needs in oncology care. By prioritizing research and development, Accuray aims to remain at the forefront of the industry, ensuring that patients receive the best possible care throughout their treatment journey.

As the healthcare landscape evolves, Accuray demonstrates its resolve to lead in the field of personalized radiotherapy. The introduction of the Accuray Stellar Solution marks a significant step forward in delivering tailored cancer care, reaffirming the company’s mission to enhance patient outcomes through innovative technology.